Yi Aiikang Capsule Regulatory Proteins For HIV Tat, Rev Impact Study Of Gene Expression

Objective: Based on profit Yi aikang capsule in patients with HIV/AIDS clinicalcurative effect, regulatory proteins from HIV Tat, Rev gene expression as abreakthrough point, to explore profit Yi aikang capsule on the influence of peopleliving with HIV virus control protein gene expression, reveal the clinical curativeeffect of Yi aikang capsule mechanism.Methods: This study were to observe205cases of HIV/AIDS patients and109cases of male, female96cases, according to the inclusion criteria, according to thedoctor order with random number table were randomly divided into two groups:treatment group (Chinese traditional medicine group)135cases,70cases of controlgroup (placebo). Treatment group take profit Yi aikang capsule, five at a time, threetimes a day, oral; Control group take profit Yi aikang capsule simulation agent, takingmethods and the treatment group. On the same day as the start date of treatment andobservation,3months for one period of treatment, two courses of continuousobservation, respectively in the treatment of0,3,6months to visit. Patients into thegroup recorded when the baseline data, detection of safety index. Since then each timeyou visit record the change of the main symptoms. Unless severe adverse reactions,observation date generally does not change. To have serious adverse reaction andsafety check after treatment has obvious anomaly in abnormal value should befollowed up and the project for review. On this basis, from two groups of randomlyselected40patients with laboratory tests, including17cases in treatment group,control group of23cases, lines of Real-time PCR detection, observe the Yi aikangcapsule for HIV control gene Tat, the influence of the Rev. Results:1, the two groups before treatment symptoms integral is no statisticalsignificance (P>0.05), treatment group after treatment of fatigue, fever, coldevil/chills, sweat out abnormal, insomnia, dizziness, loss of appetite score wasstatistically significant (P<0.05), the control group of insomnia, sore throats, integralwas statistically significant (P<0.05), compared the two groups after treatmentsymptoms integral was statistically significant (P<0.05).2, the comparison of the twogroups before treatment CD4+T lymphocyte count no statistical significance (P>0.05),treatment group after treatment, and control within the way is no statisticalsignificance (P>0.05), but the treatment group of CD4+T cell count down withoutcontrol group obviously, the two groups after treatment compared with no statisticalsignificance (P>0.05).3, two groups before treatment viral load no statisticalsignificance (P>0.05), treatment group after treatment, and control within the way isno statistical significance (P>0.05), but the treatment group viral load decline than thecontrol group obviously, the two groups after treatment compared with no statisticalsignificance (P>0.05).4, Tat gene expression of the two groups before treatment is nostatistical significance (P>0.05), treatment group after treatment Tat amount of geneexpression was statistically significant (P<0.05), control group not significant(P<0.05), comparing the two groups after treatment was statistically significant(P<0.05).5, Rev gene expression of the two groups before treatment is no statisticalsignificance (P>0.05), treatment group after treatment Rev amount of gene expressionwas statistically significant (P<0.05), control group not significant (P<0.05),comparing the two groups after treatment was statistically significant (P<0.05).Conclusion:1,Yi aikang capsule can obviously improve the patient’s clinicalsymptoms, including to fatigue, fever, cold evil/chills, sweat out abnormal, thesymptom such as insomnia, dizziness, loss of appetite is especially significantimprovement;2,stable profit Yi aikang capsule has infected CD4+Tlymphocyte count and viral load trendt;3,the mechanism of action of beneficial Yiaikang protein may be related to regulation of HIV control Tat, Revgene expression changes.